Eyebright Medical(SH:688050) Chang Jiang Shang Bao·2026-02-27 00:07Core Viewpoint - Aibo Medical (688050.SH) is seeking growth by acquiring a controlling stake in Demai Medical, a leading company in sports medicine, for 683 million yuan, aiming to diversify its revenue sources beyond ophthalmic medical devices [1][7]. Group 1: Acquisition Details - Aibo Medical plans to acquire 68.31% of Demai Medical using a combination of acquisition loans and its own funds, with the total transaction value set at 683 million yuan [1][5]. - Demai Medical is valued at 1.074 billion yuan, reflecting a significant premium of 343.29% [3][5]. - The acquisition is expected to add approximately 500 million yuan in goodwill to Aibo Medical's balance sheet [1][8]. Group 2: Financial Performance - For the first three quarters of 2025, Aibo Medical reported revenues of 1.144 billion yuan, a year-on-year increase of 6.43%, but net profits decreased by 8.64% to 290 million yuan [1][7]. - In the third quarter of 2025, Aibo Medical's revenue fell by 8.17% to 358 million yuan, with net profits declining by 29.85% [8]. - Aibo Medical's financial expenses increased by 16.36% to 13.88 million yuan for the first three quarters of 2025 [9]. Group 3: Demai Medical's Performance and Projections - Demai Medical is projected to achieve revenues of 236 million yuan and 286 million yuan in 2024 and 2025, respectively, with adjusted net profits of approximately 9.29 million yuan and 23.60 million yuan [4]. - The company has made performance commitments, promising cumulative net profits of at least 165 million yuan over three years from 2026 to 2028 [7]. Group 4: Risks and Financial Implications - The acquisition will lead to an increase in interest-bearing liabilities, as 70% to 80% of the acquisition cost will be financed through loans, potentially impacting Aibo Medical's financial burden [2][8]. - If Demai Medical fails to meet its performance targets, Aibo Medical may face risks related to goodwill impairment [1][8].